A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Data on the effectiveness of antipsychotics in the early phase of schizophrenia are limited. The authors examined the risk of rehospitalization and drug discontinuation in a nationwide cohort of 2,588 consecutive patients hospitalized for the first time with a diagnosis of schizophrenia between 2000 and 2007 in Finland. METHOD: The authors linked national databases of hospitalization, mortality, and antipsychotic prescriptions and computed hazard ratios, adjusting for the effects of sociodemographic and clinical variables, the temporal sequence of the antipsychotics used, and the choice of the initial antipsychotic for each patient. RESULTS: Of 2,588 patients, 1,507 (58.2%) collected a prescription for an antipsychotic during the first 30 days after hospital discharge, and 1,182 (45.7%, 95% confidence interval [CI]=43.7-47.6) continued their initial treatment for 30 days or longer. In a pairwise comparison between depot injections and their equivalent oral formulations, the risk of rehospitalization for patients receiving depot medications was about one-third of that for patients receiving oral medications (adjusted hazard ratio=0.36, 95% CI=0.17-0.75). Compared with oral risperidone, clozapine (adjusted hazard ratio=0.48, 95% CI=0.31-0.76) and olanzapine (adjusted hazard ratio=0.54, 95% CI=0.40-0.73) were each associated with a significantly lower rehospitalization risk. Use of any antipsychotic compared with no antipsychotic was associated with lower mortality (adjusted hazard ratio=0.45, 95% CI=0.31-0.67). CONCLUSIONS: In Finland, only a minority of patients adhere to their initial antipsychotic during the first 60 days after discharge from their first hospitalization for schizophrenia. Use of depot antipsychotics was associated with a significantly lower risk of rehospitalization than use of oral formulations of the same compounds. Among oral antipsychotics, clozapine and olanzapine were associated with more favorable outcomes. Use of any antipsychotic was associated with lower mortality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 2×
“2% of patients did not regularly take medication as prescribed (8), that prescription completion rates ranged from 28% to 85% (9), and that irregular medication use rates ranged from 31% to 62% (9).”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Self-citationRobinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Self-citationMedication adherence of individuals with a first episode of psychosis
Coldham, E. L., Addington, J., & Addington, D. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.02437.x · Cited by 413
Research works printed but not linked: 4
- National Institute for Health and Clinical Excellence (NICE), 2009, Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), Final Version (NICE Clinical Guideline 82)
- Young JL, 1986, Bull Am Acad Psychiatry Law, 14, 105
- Young JL, 1999, J Am Acad Psychiatry Law, 27, 426
- 10.1176/ps.2007.58.4.482 · doi:10.1176/ps.2007.58.4.482 · Paper page
Cited by
Items 301–400 of 618
Antipsychotic utilisation and persistence in Australia: A nationwide 5-year study
Taylor, M., Dangelo-Kemp, D., Liu, D., Kisely, S. R., Graham, S., Hartmann, J., & Colman, S. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211051618 · Cited by 15
Self-citationThe safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia
Kahn, R. S., & Giannopoulou, A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1070670 · Cited by 16
Two cases of long-acting paliperidone in adolescence
Fàbrega, M. G. I., Sugranyes, G., & Baeza, I. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315600141 · Cited by 13
Mauri, M. C., Reggiori, A., Minutillo, A., Franco, G., Pace, C. D., Paletta, S., & Cattaneo, D. (2020) · Pharmacopsychiatry · doi:10.1055/a-1113-7862 · Cited by 14
Kane, J. M., Agid, O., Castle, D. J., Citrome, L., Fagiolini, A. M., Kishimoto, T., Larrauri, C. A., Leucht, S., Rubio, J. M., Sajatovic, M., et al. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00838-3 · Cited by 20
Denissoff, A., Taipale, H. T., Tiihonen, J., Forti, M. D., Mittendorfer‐Rutz, E., Tanskanen, A. J., Mustonen, A., & Niemelä, S. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae034 · Cited by 13
Self-citationLintunen, J., Hamina, A., Lähteenvuo, M., Paljärvi, T., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13762 · Cited by 14
Self-citationLi, P., Geng, Z., Benson, C. J., Patel, C. A., & Doshi, J. A. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03075-6 · Cited by 18
Xiao, L., Zhao, Q., Li, A., Sun, J., Wu, B., Wang, L., Zhang, H., Zhang, R., Li, K., Xu, X., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06044-x · Cited by 12
Harlin, M., Chepke, C., Larsen, F., Lynum, K. S. B., Chumki, S. R., Fitzgerald, H. M., Such, P., Madera‐McDonough, J., Yildirim, M., Panni, M. K., et al. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s412357 · Cited by 11
Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
Pae, C., Wang, S., Han, C., Paktar, A., Masand, P. S., & Lee, S.-J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s52486 · Cited by 12
Godman, B., Persson, M., Miranda, J., Barbui, C., Bennie, M., Finlayson, A. E. T., Raschi, E., & Wettermark, B. (2013) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12025 · Cited by 11
Fagiolini, A. M., Alfonsi, E., Amodeo, G., Cenci, M., Lella, M. D., Farinella, F., Ferraiuolo, F., Fraguas, D., Loparco, N., Gutiérrez-Rojas, L., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1155553 · Cited by 12
Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
Carpiniello, B., & Pinna, F. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s86301 · Cited by 12
Three-month paliperidone palmitate - a new treatment option for schizophrenia
Bernardo, M., & Bioque, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1191945 · Cited by 14
Ojagbemi, A., Chiliza, B., Bello, T., Asmal, L., Esan, O., Emsley, R. A., & Gureje, O. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00172 · Cited by 12
Horvitz-Lennon, M. V., Predmore, Z., Orr, P. T., Hanson, M., Hillestad, R. J., Durkin, M., Kim, E., & Mattke, S. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12770 · Cited by 13
Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital
Olayinka, O. O., Oyelakin, A., Cherukupally, K., Virk, I., Ojimba, C., Khadka, S., Maksymenko, A., Fouron, P., Khandaker, T., Olupona, T., et al. (2019) · Psychiatry Journal · doi:10.1155/2019/8629030 · Cited by 13
Factors that Impact Caregivers of Patients with Schizophrenia.
Strunoiu, L. M., Strunoiu, C. M., Chirita, A., Pîrlog, M. C., & Tica, A. A. (2019) · Europe PMC (PubMed Central) · doi:10.12865/chsj.45.03.09 · Cited by 14
Roopun, K. R., Tomita, A. M., & Paruk, S. (2020) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v26i0.1509 · Cited by 17
Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia
Rubio, J. M., Malhotra, A. K., & Kane, J. M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113099 · Cited by 14
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2021) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001299 · Cited by 15
Pharmakologische Langzeitbehandlung schizophrener Erkrankungen
Deutschenbaur, L., Lambert, M., Walter, M., Naber, D., & Huber, C. G. (2014) · Der Nervenarzt · doi:10.1007/s00115-013-3807-7 · Cited by 13
Barnes, T. R. E., Drake, R., Dunn, G., Hayhurst, K. P., Jones, P. B., & Lewis, S. W. (2013) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.125807 · Cited by 12
Penttilä, M. (2013) · Cited by 11
Patel, R., Brinn, A., Irving, J., Chaturvedi, J., Gudiseva, S., Correll, C. U., Fusar‐Poli, P., & McGuire, P. K. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231211575 · Cited by 11
Wang, Y., Harlin, M., Larsen, F., Wang, X., Park, W., Rich, B., Gobburu, J. V. S., & Raoufinia, A. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1397 · Cited by 12
Sacchetti, E., & Vita, A. (2013) · Springer eBooks · doi:10.1007/978-88-470-2679-7_1 · Cited by 14
Buhagiar, K., Templeton, G., Blyth, H., Dey, M., & Giacco, D. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.08.026 · Cited by 14
Clozapine prescription rates in Southeast Europe: A cross-sectional study
Russo, M., Ristić, D. I., Cohen, D., Arënliu, A., Bajraktarov, S., Kulenović, A. D., Stevović, L. I., Marić, N. P., Novotni, A., & Jovanović, N. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123246 · Cited by 13
Strålin, P., & Hetta, J. E. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12697 · Cited by 12
Chang, J., Kim, J. A., Kim, K., Choi, S., Kim, S. M., Nam, Y.-Y., Park, S., Goo, A. J., & Park, S. M. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102161 · Cited by 13
Benarous, X., Cottin, G., Lahaye, H., de la Rivière, S. G., Guilé, J.-M., Speranza, M., Bonnot, O., & Cohen, D. (2022) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0124 · Cited by 14
Kim, Y., Wang, S., Kwak, K., Yoon, H.-K., Pae, C., Kim, J.-J., & Bahk, W. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.4.371 · Cited by 11
Vgontzas, A. N., Paschalidou, A., Simos, P. G., Anastasaki, M., Zografaki, A., Volikos, E., Koutra, K., & Basta, M. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115676 · Cited by 12
Risperidone ISM ® : review and update of its usefulness in all phases of schizophrenia
Messer, T., Bernardo, M., Anta, L., & Martínez, J. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241280046 · Cited by 12
Correll, C. U. (2025) · CNS Spectrums · doi:10.1017/s1092852925100503 · Cited by 15
Popp, B. S., Manea, M. M., & Moraru, M. O. (2014) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-292 · Cited by 10
Gisev, N., Bell, J. S., & Chen, T. F. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12276 · Cited by 11
Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia
Rosso, G., Pessina, E., Martini, A., Salvo, G. D., & Maina, G. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000494 · Cited by 10
A Study on Factors Related to Long-term Hospitalization in Patients with Chronic Schizophrenia
Jang, O.-J., Lee, B. D., & Chung, Y. (2015) · 신경정신의학 · doi:10.4306/jknpa.2015.54.1.76 · Cited by 10
Horvitz-Lennon, M. V., Alegria, M. M., & Normand, S. T. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201100408 · Cited by 11
Long-Acting Injectable Antipsychotics and the Management of Nonadherence
Weiden, P. J., Solari, H., Kim, S., & Bishop, J. R. (2011) · Psychiatric Annals · doi:10.3928/00485713-20110425-06 · Cited by 10
Cost Reductions Associated With Long-Acting Injectable Antipsychotics According to Patient Age
Stip, É. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16lr11402 · Cited by 9
Doshi, J. A., Li, P., Geng, Z., Seo, S., Patel, C. A., & Benson, C. J. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20230142 · Cited by 9
Medisinfrie sykehusposter – et kunnskapsløst tiltak
Røssberg, J. I., Andreassen, O. A., & Ilner, S. O. (2017) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.0091 · Cited by 9
Montemagni, C., Favero, E. D., Cocuzza, E., Vischia, F., & Rocca, P. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221122526 · Cited by 11
Chan, H., Huang, C., Feng, W., & Yen, Y. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12294 · Cited by 12
Alphs, L. D., Bossie, C. A., Fu, D., Ma, Y.-W., & Sliwa, J. K. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.909409 · Cited by 10
Suetani, S., Foo, E., & Wilson, D. (2014) · Australasian Psychiatry · doi:10.1177/1039856214539859 · Cited by 9
Patel, C. A., Khoury, A. E., Huang, A., Wang, L., & Bashyal, R. (2020) · Current Therapeutic Research · doi:10.1016/j.curtheres.2020.100587 · Cited by 9
Wong, M. M. C., Chung, A. K. K., Yeung, T. M. H., Wong, D. T. W., Lee, C. K., Lai, C. L. E., Chan, G. F. Y., Mak, G. K. L., Wong, J. O. Y., Ng, R., et al. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13374 · Cited by 10
Edinoff, A. N., Nix, C. A., Fort, J. M., Kimble, J., Guedry, R., Thomas, G., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Psychiatry International · doi:10.3390/psychiatryint3010003 · Cited by 11
Peitl, V., Margetić, B. A., Vidrih, B., & Karlović, D. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.1.118 · Cited by 9
Underuse of recommended treatments among people living with treatment-resistant psychosis
Lappin, J., Davies, K., O׳Donnell, M., & Walpola, I. C. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.987468 · Cited by 11
Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis
Solanes, A., Mezquida, G., Janssen, J., Amoretti, S., Lobo, A., González-Pinto, A. M., Arango, C., Vieta, E., Castro‐Fornieles, J., Bergé, D., et al. (2022) · Schizophrenia · doi:10.1038/s41537-022-00309-w · Cited by 11
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2022) · Biomedicines · doi:10.3390/biomedicines11010042 · Cited by 13
Patients' acceptance of the deltoid application of risperidone long-acting injection
Heres, S., Froböse, T., Hamann, J., Leucht, S., Maino, K., Reichhart, T., Stiegler, M., & Kissling, W. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.014 · Cited by 9
Review of depot aripiprazole for schizophrenia
El-Mallakh, R. S., Motiwala, F. B., & Siscoe, K. S. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s32972 · Cited by 9
PerserisTM: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.
Karas, A., Burdge, G., & Rey, J. A. (2019) · Europe PMC (PubMed Central) · Cited by 14
Antipsychotic Prescription Filling in Patients With Schizophrenia or Schizoaffective Disorder
Reutfors, J., Brandt, L., Stephansson, O., Kieler, H., Andersen, M. T., & Bodén, R. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182a1cd2e · Cited by 12
Correll, C. U., Rubio, J. M., Citrome, L., Mychaskiw, M. A., Thompson, S., Franzenburg, K. R., Suett, M., Kotak, S. V., & Kane, J. M. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s477674 · Cited by 8
Hansen, H. G., Speyer, H., Stürup, A. E., Hjorthøj, C. R., Öngür, D., Nordentoft, M., & Albert, N. (2024) · Psychological Medicine · doi:10.1017/s0033291724002678 · Cited by 8
Fang, C. Z., Chan, J. K. N., Solmi, M., Wong, C. S. M., Lui, S. S. Y., Correll, C. U., & Chang, W. C. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.05.003 · Cited by 9
Productivity and deadweight losses due to relapses of schizophrenia in Japan
Nakamura, Y., & Mahlich, J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s138033 · Cited by 9
Mutlu, E., Doğan, M. K., Ertuğrul, A., & Yağcıoğlu, A. E. A. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001526 · Cited by 8
Lorenzo, R. D., Iorio, A., Pinelli, M., Magarini, F. M., Marchi, M., Sacchetti, A., Calogero, C., Galeazzi, G. M., Ferri, P., Rovesti, S., et al. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s356341 · Cited by 9
Tidmore, L. M., Keast, S. L., Waters, H. C., Pareja, K., Cothran, T., & Skrepnek, G. H. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2101819 · Cited by 8
Kim, S., Lee, B. J., Cheon, E., Won, S., Jo, A., Kim, J., & Chung, Y. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2023.21.1.57 · Cited by 10
Ciudad, A., Bernardo, M., San, Olivares, J. M., Dilla, Polavieja, Gilaberte, & Álvarez (2011) · Patient Preference and Adherence · doi:10.2147/ppa.s26253 · Cited by 8
The Field of Schizophrenia: Strengths, Weaknesses, Opportunities, and Threats
Kane, J. M., Cornblatt, B. A., Correll, C. U., Goldberg, T. E., Lencz, T., Malhotra, A. K., Robinson, D. G., & Szeszko, P. R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr131 · Cited by 9
Hargarter, L., Lahaye, M., Chérubin, P., Lambert, M., Swarz, M., Joldygulov, G., Vischia, F., Chomskaya, V., Bozikas, V. P., Tsapakis, E.-M., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1315176 · Cited by 8
Fefeu, M., de Maricourt, P., Cachia, A., Hoertel, N., Vacheron, M.-N., Wehbe, E., Rieu, C., Olié, J., Krebs, M., Gaillard, R., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.09.041 · Cited by 11
Lorant, V., Grard, A., Audenhove, C. V., Leys, M., & Nicaise, P. (2018) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-018-0910-x · Cited by 12
Üçok, A., Yağcioğlu, A. E. A., Aydın, M., Kara, İ. A., Erbasan, V., Türkoğlu, Ö., Ergün, S., Chousein, M. G., Erdoğan, N. O., Uçar, N., et al. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000348 · Cited by 8
Díaz-Fernández, S., López-Muñoz, F., & Fernández-Miranda, J. J. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000581 · Cited by 10
Routine quality care assessment of schizophrenic disorders using information systems
Lora, A., Monzani, E., Ibrahim, B., Soranna, D., & Corrao, G. (2016) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzw096 · Cited by 15
Ye, W., Ascher‐Svanum, H., Tanji, Flynn, & Takahashi (2011) · Patient Preference and Adherence · doi:10.2147/ppa.s26002 · Cited by 8
Raftery, M. N., Burke, K., Murray, N., O’Duinn, O., Murray, I., & Hallahan, B. P. (2016) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2016.19 · Cited by 8
Gaughran, F., Stahl, D. R., Patel, A. K., Ismail, K., Smith, S. M., Greenwood, K., Atakan, Z., Gardner-Sood, P., Stringer, D., Hopkins, D., et al. (2020) · Programme Grants for Applied Research · doi:10.3310/pgfar08010 · Cited by 10
Lee, S., & Schwartz, S. E. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114277 · Cited by 8
Use of medication algorithms in first episode psychosis: a naturalistic observational study
Yeisen, R. A. H., Joa, I., Johannessen, J. O., & Opjordsmoen, S. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12203 · Cited by 8
Salem, A., Kushnier, A., Dorio, N. B., & Reeves, R. (2015) · PubMed · Cited by 8
Why we should use long-acting injectable antipsychotics more frequently
Maia‐de‐Oliveira, J. P., Bressan, R. A., Elkis, H., Machado‐de‐Sousa, J. P., & Hallak, J. E. C. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-3503 · Cited by 8
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Schizophrenia treatment preferences of psychiatrists versus guidelines: A European perspective
Kuzman, M. R., Nordentoft, M., Raballo, A., Mohr, P., Fiorillo, A., Dom, G., Mihajlović, G., Jendričko, T., Chumakov, E. M., Bajraktarov, S., et al. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2025.10072 · Cited by 8
Belge, J.-B., & Sabbe, B. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2329743 · Cited by 7
Horvitz-Lennon, M. V., Predmore, Z., Orr, P., Hanson, M., Hillestad, R. J., Durkin, M., Khoury, A. C. E., & Mattke, S. (2019) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-019-00990-7 · Cited by 11
Kokurcan, A., Güriz, S. O., Karadağ, H., Erdi, F., & Örsel, S. (2021) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2021.1879157 · Cited by 9
Cristarella, T., Castillon, G., Nepveu, J.-F., & Moride, Y. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.915 · Cited by 6
Kaur, R., Sidana, A. K., Malhotra, N., & Tyagi, S. (2023) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_389_22 · Cited by 9
Yu, H. H., Sun, Y., Qin, M., Ren, J., Yu, K., Jin, S., Zhou, Y.-Q., & Liu, L. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05023-0 · Cited by 7
Furiak, N. M., Gahn, J. C., Klein, R. W., Camper, S. B., & Summers, K. H. (2012) · Annals of General Psychiatry · doi:10.1186/1744-859x-11-29 · Cited by 8
Switching away from pipotiazine palmitate: a naturalistic study
Mustafa, F. A. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316672575 · Cited by 7
Tchobaniouk, L. V., McAllister, E., Bishop, D. L., Carpentier, R., Heins, K. R., Haight, R. J., & Bishop, J. R. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s192418 · Cited by 7
Using Claims Data to Assess Treatment Quality of First-Episode Psychosis
Reist, C., Valdés, E. G., Ren, Y., Wright, A. F., & Rubio, J. M. (2020) · Psychiatric Services · doi:10.1176/appi.ps.201900595 · Cited by 9
A stitch in time: 3-monthly long-acting injectable paliperidone palmitate in schizophrenia
Taylor, M., & Huang, H. C.-H. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317721874 · Cited by 7
Self-citationSchwartz, S. E., Lee, S., Coble, E. B., Troxler, C., Toscano, S., & Kumar, A. (2023) · Early Intervention in Psychiatry · doi:10.1111/eip.13384 · Cited by 6
Bardi, F., Moccia, L., Kotzalidis, G. D., Boggio, G., Brugnami, A., Sfratta, G., Janiri, D., Sani, G., & Simonetti, A. (2025) · Healthcare · doi:10.3390/healthcare13141709 · Cited by 9
González, G. P., Moscoso, N. S., & Lago, F. P. (2017) · PharmacoEconomics - Open · doi:10.1007/s41669-017-0058-8 · Cited by 7
Metadata
- Authors
- Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P.
- Affiliations
- NHS Lothian (GB)
- Venue
- American Journal of Psychiatry
- Published
- 2011-06
- Volume
- 168
- Issue
- 6
- Pages
- 603-609
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2160096204
- Cited by
- 619
- References
- 28
- Citations by year
- 2026: 21 · 2025: 30 · 2024: 21 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 32 · 2019: 42 · 2018: 51 · 2017: 55 · 2016: 39 · 2015: 52 · 2014: 42 · 2013: 61 · 2012: 44
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, long-acting injectable antipsychotics, oral antipsychotics, hospital readmission, treatment discontinuation, clozapine, olanzapine, risperidone, mortality, medication adherence, first hospitalization
- MeSH terms
- Administration, Oral, Adolescent, Adult, Delayed-Action Preparations, Drug Implants, Finland, Hospitalization, Humans, Injections, Middle Aged, Patient Readmission, Schizophrenia, Antipsychotic Agents, Cohort Studies, Treatment Outcome, Secondary Prevention, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.